Itacitinib + Ruxolitinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MPN (Myeloproliferative Neoplasms)
Conditions
MPN (Myeloproliferative Neoplasms)
Trial Timeline
Jan 26, 2018 → Jun 1, 2021
NCT ID
NCT03144687About Itacitinib + Ruxolitinib
Itacitinib + Ruxolitinib is a phase 2 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is completed. This product is registered under clinical trial identifier NCT03144687. Target conditions include MPN (Myeloproliferative Neoplasms).
What happened to similar drugs?
0 of 1 similar drugs in MPN (Myeloproliferative Neoplasms) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03144687 | Phase 2 | Completed |
Competing Products
6 competing products in MPN (Myeloproliferative Neoplasms)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib | Incyte | Phase 2 | 32 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 24 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 24 |
| itacitinib | Incyte | Phase 2 | 32 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 37 |
| Pemigatinib | Incyte | Phase 2 | 32 |